The pharmaceutical industry is currently facing a significant challenge—the lack of innovative drug development processes to keep pace with tremendous advances in basic science. Accordingly, there is a strong current need to reduce the cost of drug development and to increase productivity. Invitrox Technologies is in possession of proprietary technology with an extraordinary potential to decrease early attrition rates, improve productivity, and provide a cost-effective and efficient process in drug development. The Company intends to use its two technology platforms to develop and deliver novel in vitro diagnostic and therapeutic assays to the medical community.
Invitrox Technologies, Inc., located in Research Park Triangle, North Carolina, is a company dedicated to providing diagnostic and therapeutic assays that offer a higher degree of specificity and sensitivity than current methods. The lead technology platform, EQELS™, accompanied by a portfolio of associated assays, will be the Company’s first priority for FDA approval, followed by a second platform, ISADE™. Invitrox Technologies is uniquely positioned to participate in the era of personalized medicine by developing specific assays that better identify drug targets. The Company’s unique technology will allow more flexibility in drug design and targeting, resulting in more efficient drug development.